Our results suggest that the targeted form of IL-27 may be utilized as a strategy impacting cell translation initiation through modulating the eIF2α pathway (ER stress leading to apoptosis) as a novel approach for treating prostate cancer. This evidence concerns the gene EIF2A and prostate carcinoma.